Discover
Rubraca (rucaparib) / ClovisRucaparib improves postprogression outcomes in non-BRCA HRR mutated ovarian cancer (OncLive) - Apr 6, 2020 - P3, N=564; ARIEL3 (NCT01968213); Sponsor: Clovis Oncology; "Treatment with rucaparib versus placebo was associated with improvements in postprogression efficacy end points in patients with tumors associated with non-BRCA HRR gene mutation. Time to disease progression on subsequent line of therapy or death favored treatment with rucaparib at 21.1 months versus 17.3 months with placebo (HR, 0.30; 95% CI, 0.12-0.72. The chemotherapy-free interval was 18.2 months versus 7.7 months, respectively (HR, 0.21; 95% CI, 0.09-0.52)."
CX-2009 / CytomX, Immunogen; Yervoy (ipilimumab) / Ono Pharma, BMSCOVID-19 continues to impact enrollment and recruitment of clinical trial patients (BioSpace) - Apr 10, 2020 - "Bay Area-based CytomX has paused new patient enrollment, as well as the activation of new clinical sites in a Phase I/II study of CX-2009, a CD166-targeting Probody drug conjugate, for various types of cancer. CytomX also made the decision to terminate the PROCLAIM-CX-072-002 study evaluating the anti-PD-L1 Probody CX-072 in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) in melanoma."
Tecentriq (atezolizumab) / RocheATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (clinicaltrials.gov) - Apr 9, 2020 - P3; N=614; Active, not recruiting; Sponsor: ARCAGY/ GINECO GROUP; Trial primary completion date: Sep 2020 --> Jun 2021
